In recent years, epigenetic clocks based on DNA methylation have evolved from research tools to widely used biomarkers of biological ageing. They correlate not only with chronological age, but also – depending on the “clock generation” – with morbidity, functional outcomes and mortality risks. At the same time, the step into clinical routine is challenging: measurement accuracy, comparability between tests, population generalizability and clinical decision limits have so far only been partially standardized.
Publikation
- Longevity-Special
You May Also Like
- Autoimmune Liver Diseases
Innovative Treatment Approaches for PBC, PSC, and AIH: What’s New?
- Myelofibrosis
Mutations and Molecular Diagnostics in Treatment Decisions
- Psoriasis in the Age of Precision Medicine
Systemic Therapy for Patients with Comorbidities: What Is the Best Choice?
- The AMALFI study and the limits of digital screening for atrial fibrillation
Remote monitoring for atrial fibrillation: lots of detection, little stroke prevention?
- MASH
Pharmacotherapies as “Game Changers”—What Are the Upcoming Challenges?
- Obesity Treatment
Oral GLP-1 Therapies: ATTAIN-1 and OASIS-4—The Next Leap Forward
- Older patients with atopic dermatitis
Why the Use of Biologics Is Recommended
- Disorders of the Gut-Brain Interaction